Chembio Diagnostics has earned the CE Mark for its point-of-care Dual Path Platform (DPP) multiplex test for the Zika, dengue and chikungunya viruses.

The diagnostic provides simultaneous detection of the antibodies for active and prior exposure to the viruses — an important distinction for treatment.

The test uses a small drop of blood from the fingertip and works in conjunction with the company’s DPP Micro Reader device to provide results in approximately 15 minutes.